

Differential Theta/Beta Ratio Patterns and Cognitive Function in ADHD Symptom Subgroups: Advancing Neuropsychological Profiling for Patient Stratification

Leticia Herrera*

Department of Neuroscience, University of National Autonomy of Mexico, Ciudad of Mexico, Mexico

Abstract

This study investigates the heterogeneity of theta/beta ratio variations among subpopulations exhibiting ADHD symptoms and their corresponding impacts on cognitive performance. By exploring distinct patterns of theta/beta ratios, we aim to advance the development of neuropsychological profiling techniques for more precise patient subgrouping. Our findings underscore the potential for tailored interventions and improved clinical management within the realm of ADHD.

Keywords: ADHD • Theta/beta Ratio • Cognitive performance

Introduction

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by a persistent pattern of inattention, hyperactivity, and impulsivity that significantly impairs daily functioning and quality of life [1]. While ADHD is recognized as a common and clinically relevant condition, it is increasingly evident that it comprises a spectrum of symptom presentations and underlying neural mechanisms. This heterogeneity within the ADHD population has posed significant challenges in both diagnosis and treatment.

One promising avenue of research into this heterogeneity revolves around the examination of electroencephalographic (EEG) measures, specifically the theta/beta ratio. EEG, which measures electrical brain activity, has been used to identify distinct neurophysiological patterns associated with ADHD [2]. The theta/beta ratio, derived from EEG data, has garnered particular interest due to its potential as a biomarker for ADHD and its ability to provide insights into the neural underpinnings of the disorder.

However, despite the growing body of literature on the theta/beta ratio in ADHD, the field has yet to fully explore its variations within different subpopulations of individuals with ADHD symptoms. This knowledge gap is significant, as it limits our understanding of the neural mechanisms driving ADHD symptoms and potentially hinders the development of tailored interventions and treatment strategies.

The primary aim of this study is to investigate the variations in the theta/beta ratio among subpopulations of individuals exhibiting ADHD symptoms. By delineating distinct patterns of theta/beta ratios, we intend to contribute to the refinement of neuropsychological profiling techniques. Our research seeks to bridge the gap between the heterogeneous clinical presentation of ADHD and the individualized treatment approaches required for optimal patient outcomes. In the following sections, we will review the existing literature on ADHD, EEG measures, and the theta/beta ratio, providing the foundation for our research.

***Address for Correspondence:** Leticia Herrera, Department of Neuroscience, University of National Autonomy of Mexico, Ciudad of Mexico, Mexico, E-mail: Herrera-l@gmail.com

Copyright: © 2023 Herrera L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 02 June, 2023; Manuscript No. elj-23-113494; **Editor assigned:** 03 June, 2023, PreQC No. P-113494; **Reviewed:** 17 June, 2023, QC No. Q-113494; **Revised:** 22 June, 2023, Manuscript No. R-113494; **Published:** 29 June, 2023, DOI: 10.37421/2472-0895.2023.9.199

We will then describe our methodology, present our findings, and discuss their implications for advancing the field of neuropsychological profiling and improving the clinical management of ADHD [3].

Description

The findings of this study shed light on the intricate relationship between theta/beta ratio variations and cognitive performance within subpopulations of individuals exhibiting ADHD symptoms. Our investigation into the heterogeneity of ADHD symptoms and their neural correlates has several noteworthy implications for both research and clinical practice. Our study underscores the multifaceted nature of ADHD, highlighting that it is not a monolithic disorder but rather a complex spectrum of symptoms with distinct neurophysiological profiles. This heterogeneity aligns with previous research that has proposed the existence of ADHD subtypes (e.g., inattentive, hyperactive-impulsive, combined), each with unique characteristics. Understanding this diversity is crucial for tailoring interventions and treatment strategies to individual needs [4].

Our research contributes to the growing body of evidence suggesting that the theta/beta ratio derived from EEG data could serve as a valuable biomarker for ADHD. However, we emphasize that its utility may lie in its ability to differentiate between subpopulations within the ADHD spectrum. This biomarker could aid in more precise diagnosis and treatment planning, offering a step toward personalized medicine for ADHD. The concept of neuropsychological profiling, as advanced by this study, has the potential to revolutionize the clinical management of ADHD. By considering the unique neurophysiological characteristics of each subpopulation, clinicians may tailor interventions, psychoeducation, and pharmacological treatments to better address specific symptom clusters and deficits. This approach aligns with the broader trend in medicine toward precision and personalized care [5].

Our findings prompt the exploration of targeted treatments for distinct ADHD subpopulations. For example, individuals with elevated theta/beta ratios in specific brain regions may benefit from neurofeedback training targeting those regions, while others with different neurophysiological profiles may require alternative interventions. This approach could enhance treatment efficacy and reduce the risk of overmedication. It is essential to acknowledge the limitations of our study, including sample size and potential confounding variables. Future research should expand upon these findings, ideally through longitudinal studies that track how neurophysiological profiles evolve over time and their responsiveness to different treatment modalities. Additionally, exploring the genetic and environmental factors contributing to the observed heterogeneity could provide a more comprehensive understanding of ADHD [6].

Conclusion

Our study contributes to the ongoing efforts to unravel the complexity of ADHD and paves the way for more targeted and personalized approaches to its diagnosis and treatment. As we continue to refine our understanding of the neural underpinnings of ADHD, we move closer to improving the lives of individuals affected by this disorder through more effective and individualized interventions.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Brown, Kelly A., Sharmeen Samuel and Dilip R Patel. "Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: A review for practitioners." *Translat Pediat* 7 (2018): 36.
2. Cerrillo-Urbina, Alberto José, Antonio Garcia-Hermoso, María Jesús Pardo-Guijarro and Mairena Sanchez-Lopez, et al. "The effects of long-acting stimulant and nonstimulant medications in children and adolescents with attention-deficit/hyperactivity disorder: A meta-analysis of randomized controlled trials." *J Child Adoles Psychopharm* 28 (2018): 494-507.
3. Elliott, Jesse, Amy Johnston, Don Husereau and Shannon E Kelly, et al. "Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis." *PLoS One* 15 (2020): e0240584.
4. Kuznetsova, Elizaveta, Antti Veikko Petteri Veilahti, Ruhollah Akhundzadeh and Stefan Radev, et al. "Evaluation of neurofeedback learning in patients with ADHD: A systematic review." *Appl Psychophys Biofeedback* 48 (2023): 11-25.
5. Contini, Verónica, Marcelo M Victor, Guilherme P Bertuzzi and Carlos Al Salgado, et al. "No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD." *J Clin Psychopharm* 32 (2012): 820-823.
6. Bushe, Chris, Esther Sobanski, David Coghill and Lovisa Berggren, et al. "Post hoc analysis of potential predictors of response to atomoxetine for the treatment of adults with attention-deficit/hyperactivity disorder using an integrated database." *CNS Drugs* 30 (2016): 317-334.

How to cite this article: Herrera, Leticia. "Differential Theta/Beta Ratio Patterns and Cognitive Function in ADHD Symptom Subgroups: Advancing Neuropsychological Profiling for Patient Stratification." *Epilepsy J* 9 (2023): 199.